共 50 条
- [1] S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodiesBRITISH JOURNAL OF CANCER, 2018, 119 (03) : 339 - 346Wagner, Nikolaus B.Forschner, AndreaLeiter, UlrikeGarbe, ClausEigentler, Thomas K.
- [2] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodiesBULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308Robert, CarolineMateus, Christina
- [3] Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patientsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Subrahmanyam, PriyankaDong, ZhiwanGusenleitner, DanielGiobbie-Hurder, AnitaSevergnini, MarianoZhou, JunManos, MichaelMaecker, HoldenHodi, F. Stephen
- [4] Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCANCER CELL, 2019, 35 (02) : 238 - +Gide, Tuba N.Quek, CameliaMenzies, Alexander M.Tasker, Annie T.Shang, PingHolst, JeffMadore, JasonLim, Su YinVelickovic, RebeccaWongchenko, MatthewYan, YibingLo, SerigneCarlino, Matteo S.Guminski, AlexanderSaw, Robyn P. M.Pang, AngelMcGuire, Helen M.Palendira, UmaimainthanThompson, John F.Rizos, Helenda Silva, Ines PiresBatten, MarcelScolyer, Richard A.Long, Georgina V.Wilmott, James S.
- [5] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodiesANNALS OF ONCOLOGY, 2021, 32 : S249 - S249Reck, Martin
- [6] CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patientsJCI INSIGHT, 2018, 3 (13):Goltz, DianeGevensleben, HeidrunVogt, Timo J.Dietrich, JoernGolletz, CarstenBootz, FriedrichKristiansen, GlenLandsberg, JenniferDietrich, Dimo
- [7] Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy responseJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Uzelac, MatthewLi, Wei TseLi, YuxiangOngkeko, Weg M.
- [8] Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter studyEUROPEAN JOURNAL OF CANCER, 2021, 157 : 361 - 372Umeda, YoshiyasuYoshikawa, ShusukeKiniwa, YukikoMaekawa, TakeoYamasaki, OsamuIsei, TaikiMatsushita, ShigetoNomura, MotooNakai, YasuoFukushima, SatoshiSaito, ShintaroTakenouchi, TatsuyaTanaka, RyoKato, HiroshiOtsuka, AtsushiMatsuya, TaisukeBaba, NatsukiNagase, KotaroInozume, TakashiOnuma, TakehiroKuwatsuka, YutakaFujimoto, NorikiKaneko, TakahideOnishi, MasazumiNamikawa, KenjiroYamazaki, NaoyaNakamura, Yasuhiro
- [9] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanomaEUROPEAN JOURNAL OF CANCER, 2024, 198Ellebaek, EvaKhan, ShawezBastholt, LarsSchmidt, HenrikHaslund, Charlotte AaquistDonia, MarcoSvane, Inge Marie
- [10] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapyEUROPEAN JOURNAL OF CANCER, 2024, 198Rogiers, AljosjaDimitriou, FlorentiaLobon, IreneHarvey, CatrionaVergara, Ismael A.da Silva, Ines PiresLo, Serigne N.Scolyer, Richard A.Carlino, Matteo S.Menzies, Alexander M.Long, Georgina V.